Lupin had also increased research and development spending to Rs 958.28 crore in FY'14 as compared to Rs 770.85 crore in the FY'13.

Nanomi has a rich talent pool of scientists who would be backed by Lupin's global R&D and manufacturing teams, the Mumbai-based firm said.

Lupin rallied as much as 4.8% in trade on Monday in a weak market, after the drugmaker reported a 42% growth in its quarterly net profit.